March 2016 Central Nervous System

ENTRESTOâ„¢ (sacubitril/valsartan) for the Management of Heart Failure

March 31, 2016

Pharmacist Education

ENTRESTOâ„¢ (sacubitril/valsartan) tablets 24/26 mg, 49/51 mg, 97/103 mg, from Novartis Pharmaceuticals Corporation, are a combination of an angiotensin receptor blocker and a novel neprilysin inhibitor, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association class II through IV) and reduced ejection fraction.

Making a Difference Through Leadership

March 23, 2016

RESPy Awards

For Evva Destine Hoover, a pharmacy student at the South Carolina College of Pharmacy, leadership roles are not positions to be filled, but opportunities to make an impact on one's community.

Navigating the Complexities of Pharmacy Reimbursement: Will We Ever Reach Transparency?

March 23, 2016

Directions in Pharmacy

Evolution in the pharmacy reimbursement system represents a crucial component toward stabilizing costs and providing fair margins for pharmacy sustainability, particularly in rural and underserved areas.

Liability for Failure to Remove Recalled Product from Inventory

March 22, 2016

Legal Focus

When a hospital fails to respond to a medication recall notice and a patient allegedly suffers major bodily damage as a result, do the statutory requirements in the state's medical malpractice act apply?

Independent Pharmacy's Future: Goal-Setting Is Key for Solvency

March 18, 2016

Directions in Pharmacy

Establishing a competitive edge against large, national retail pharmacy chains and mail order pharmacies has been one of the most significant challenges facing independent pharmacies for many years.

Spring Your Way to Healthier Outcomes

March 18, 2016

Brown Bag Consult

The beginning of spring is an ideal time to help patients review their medications and overall health than when they awake from winter hibernation" and emerge from flu season.


March 16, 2016

Rx Product News Profile

The FDA has approved Belbuca buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.